Printer Friendly

PROCYTE ANNOUNCES IMPROVED DRUG DELIVERY SCREEN FOR HAIR GROWTH DRUG FORMULATIONS

 KIRKLAND, Wash., April 21 /PRNewswire/ -- ProCyte Corp. (NASDAQ-NMS: PRCY) announced today that its scientists have developed a specific method of rapidly selecting formulations for its hair growth technology.
 The data, presented at the Third International Conference of the Prediction of Percutaneous Penetration, held in Montpellier, France, provides the company's methodology in rapidly screening and selecting hair growth formulations. Formulations, such as topically applied creams and gels, are the means by which a drug is delivered to the target site. ProCyte's investigational hair growth drug, tradenamed Tricomin, is being studied for its effect on prevention of hair loss due to androgenetic alopecia.
 According to ProCyte's director of pharmaceutical development, Dr. Ron Warner, "This model provides ProCyte with the means to learn quickly and efficiently how our hair growth drug will work in various formulations. By applying the pharmacodynamic model we can select improved formulations for delivering our drug. As a result, the company reduces the need for repetitive and costly formulation screening clinical trials.
 "Many drugs fail in clinical testing because they cannot be effectively delivered," said Warner. "The ability to improve the likelihood of a drug's deliverability as early in its development stage as possible, means improved savings in clinical trials. The drug must still undergo clinical testing, but it can now be tested with an improved chance of success because the delivery mechanism, or vehicle, will effectively get the drug to its target site."
 ProCyte scientist Dr. Christopher Ignace presented the findings of the company's work in developing the improved formulation selection model. In his presentation entitled "Impact of Vehicle Composition on Percutaneous Penetration and Hair Growth Response of a Tri and Hexapeptide Complex," Ignace outlined ProCyte's development of an in vivo pharmacodynamic model. The pharmacodynamic model shows the relationship of the drug delivery methods used to the response in the treated site.
 Industry sources estimate that over 50 million Americans suffer from androgenetic alopecia. Androgenetic alopecia refers to the genetic or hereditary thinning of hair in women and baldness in men. For both men and women, hereditary thinning begins in the teen years and is usually fully expressed by the age of 40.
 ProCyte's hair growth drug candidate is a peptide-copper compound. The company is conducting research and development of the drug, along with its corporate partner in Japan, in preparation for clinical testing.
 ProCyte Corp. is the leading developer of peptide-copper compounds for applications in wound healing and tissue repair. In addition to its hair growth program, the company is conducting clinical studies on the use of peptide-copper compounds to treat chronic dermal wounds and inflammatory bowel disease.
 -0- 4/21/93
 /CONTACT: Karen L. Hedine, vice president, of ProCyte, 206-820-4548/
 (PRCY)


CO: ProCyte Corp. ST: Washington IN: MTC SU: PDT

AL-SG -- SE002 -- 8488 04/21/93 08:34 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 21, 1993
Words:463
Previous Article:PYXIS CORP. REPORTS FIRST QUARTER RESULTS
Next Article:J. WILLIAM GRIMES ELECTED CEO OF MULTIMEDIA, INC.
Topics:


Related Articles
PROCYTE CORP. REPORTS FIRST-QUARTER FINANCIALS
PROCYTE CORPORATION NAMES TWO NEW CORPORATE OFFICERS
PROCYTE CORP. REPORTS SECOND QUARTER FINANCIALS
PROCYTE ANNOUNCES CONSTRUCTION HAS BEGUN ON REDMOND PLANT
PROCYTE DRUG PREVENTS HAIR LOSS THAT RESULTS FROM CHEMOTHERAPY TREATMENT
PROCYTE TO INITIATE HAIR DRUG CLINICAL TRIAL
PROCYTE BEGINS PHASE II HAIR DRUG CLINICAL TRIAL
CyDex, Inc. Announces Agreement With Bristol-Myers Squibb For Drug Delivery Technology
CyDex, Inc. Announces Agreement With Array BioPharma Inc.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters